Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg".
Press Release Nov 27 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Empagliflozin and Linagliptin Tablets in two dosages. The production will take place at Zydus's manufacturing facility in Ahmedabad, and the tablets had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 26 2025
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
- Press Release Nov 25 2025
- Press Release Nov 14 2025
- Press Release Nov 13 2025
Later from Zydus Lifesciences
- Press Release Dec 04 2025
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
- Press Release Dec 09 2025
- Press Release Dec 10 2025
- Press Release Dec 15 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences